Cardiac remodeling can cause ventricular dysfunction and progress to heart failure, a
cardiovascular disease that claims many lives globally. Ivabradine, a funny channel (I f) …

Heart failure with preserved ejection fraction (HFpEF) is the largest unmet clinical need in
cardiovascular medicine. Despite decades of research, the treatment option for HFpEF is still …

Heart failure (HF) is a rapidly growing public health issue with more than 37.7 million
patients worldwide and an annual healthcare cost of $108 billion. However, HF-related …

In this comprehensive state-of-the-art review, we provide an evidence-based analysis of
current drug therapies for patients with heart failure with preserved ejection fraction (HFpEF) …

Cardiac fibrosis is a pathological condition characterized by excessive deposition of
collagen and other extracellular matrix components in the heart. It is recognized as a major …

Cardiac fibrosis is a pivotal cardiovascular disease (CVD) process and represents a notable
health concern worldwide. While the complex mechanisms underlying CVD have been …

Abstract Purpose of Review Cardiac fibrosis is a crucial juncture following cardiac injury and
a precursor for many clinical heart disease manifestations. Epigenetic modulators …

Background Ivabradine improves cardiac function in patients with heart failure, but its effect
on dilated cardiomyopathy (DCM) remains unclear. We performed a systematic review and …

Background: While the prevalence of heart failure with preserved ejection fraction (HFpEF)
has increased over the last two decades, there still remains a lack of effective treatment. A …

Fibrotic disorders are defined by accumulating excessive extracellular matrix (ECM)
components, especially collagens, in various organs, leading to tissue scarring and organ …